Table 2.

Overview of treatment-emergent adverse events (TEAEs) by treatment group – safety population

TEAE n (%)	Tecemotide + Cyclophosphamide (n = 79)	Placebo + Saline (n = 42)
Any grade, n (%)	69 (87.3%)	40 (95.2%)
Grade 3/4, n (%)	23 (29.1%)	11 (26.2%)
Treatment-related, n (%)	38 (48.1%)	20 (47.6%)
Treatment-related Grade 3/4, n (%)	4 (5.1%)	0 (0%)
Fatal TEAE, n (%)	2 (2.5%)	0 (0%)

TEAEs are represented for the number (%) of patients for the two treatment arms respectively (each patient is counted once). Grading according to NCI-CTCAE Version 3.0. Abbreviations: NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events, TEAE: treatment-emergent adverse event